Monitoring NK cell activity in patients with hematological malignancies

OncoImmunology

Volumn 2, Issue 9, 2013, Pages

  Viel, Sébastien ^a,b,c,d   Charrier, Emily ^a,b,c,d   Marçais, Antoine ^a,b,c   Rouzaire, Paul ^e   Bienvenu, Jacques ^a,b,c,d   Karlin, Lionel ^d   Salles, Gilles ^d   Walzer, Thierry ^a,b,c  

^a CENTRE INTERNATIONAL DE RECHERCHE EN INFECTIOLOGIE   (France)

^b UNIVERSITÉ DE LYON   (France)

^c CNRS   (France)

^d CENTRE HOSPITALIER LYON SUD   (France)

^e UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

Author keywords

Cytotoxicity; Flow cytometry; Lenalidomide; Multiple myeloma; Natural killer cells

Indexed keywords

BORTEZOMIB; CD20 ANTIGEN; DEXAMETHASONE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 13; LENALIDOMIDE; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY IPH2101; NATURAL KILLER CELL RECEPTOR NKG2D; RANTES; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; CANCER CELL CULTURE; CANCER PATIENT; CANCER PROGNOSIS; CYTOKINE RELEASE; CYTOLOGY; DEGRANULATION; DRUG CYTOTOXICITY; FLOW CYTOMETRY; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNE RESPONSE; MULTIPLE MYELOMA; NATURAL KILLER CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHENOTYPE; PROTEIN EXPRESSION; REVIEW;

EID: 84890288919     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.26011     Document Type: Review

References (62)

1. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellström-Lindberg E, Tefferi A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114:937-51; PMID:19357394; http://dx.doi. org/10.1182/blood-2009-03-209262
2. Hanahan D, Weinberg RA. The hallmarks of cancer. [PMID]. Cell 2000; 100:57-70; PMID:10647931; http://dx.doi.org/10.1016/S0092-8674(00)81683-9
3. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011; 144:646-74; PMID:21376230; http://dx.doi.org/10.1016/j.cell.2011.02.013
4. Spits H, Artis D, Colonna M, Diefenbach A, Di Santo JP, Eberl G, Koyasu S, Locksley RM, McKenzie AN, Mebius RE, et al. Innate lymphoid cells--a proposal for uniform nomenclature. Nat Rev Immunol 2013; 13:145-9; PMID:23348417; http://dx.doi. org/10.1038/nri3365
5. Soudja SM, Ruiz AL, Marie JC, Lauvau G. Inflammatory monocytes activate memory CD8(+) T and innate NK lymphocytes independent of cognate antigen during microbial pathogen invasion. Immunity 2012; 37:549-62; PMID:22940097; http://dx.doi.org/10.1016/j.immuni.2012.05.029
6. Lucas M, Schachterle W, Oberle K, Aichele P, Diefenbach A. Dendritic cells prime natural killer cells by trans-presenting interleukin 15. Immunity 2007; 26: 503-17; PMID:17398124; http://dx.doi.org/10.1016/j.immuni.2007.03.006
7. Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nat Immunol 2008; 9:503-10; PMID:18425107; http://dx.doi.org/10.1038/ni1582
8. Kastenmüller W, Torabi-Parizi P, Subramanian N, Lämmermann T, Germain RN. A spatially-organized multicellular innate immune response in lymph nodes limits systemic pathogen spread. Cell 2012; 150:1235-48; PMID:22980983; http://dx.doi. org/10.1016/j.cell.2012.07.021
9. Diefenbach A, Raulet DH. Strategies for target cell recognition by natural killer cells. Immunol Rev 2001; 181:170-84; PMID:11513138; http://dx.doi.org/10.1034/j.1600-065X.2001.1810114.x
10. Raulet DH, Gasser S, Gowen BG, Deng W, Jung H. Regulation of ligands for the NKG2D activating receptor. Annu Rev Immunol 2013; 31:413- 41; PMID:23298206; http://dx.doi.org/10.1146/annurev-immunol-032712-095951
11. Brandt CS, Baratin M, Yi EC, Kennedy J, Gao Z, Fox B, Haldeman B, Ostrander CD, Kaifu T, Chabannon C, et al. The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans. J Exp Med 2009; 206:1495- 503; PMID:19528259; http://dx.doi.org/10.1084/jem.20090681
12. Nimmerjahn F, Ravetch JV. FcRs in health and disease. Curr Top Microbiol Immunol 2011; 350:105-25; PMID:20680807; http://dx.doi. org/10.1007/82_2010_86
13. Cremer I, Fridman WH, Sautès-Fridman C. Tumor microenvironment in NSCLC suppresses NK cells function. Oncoimmunology 2012; 1:244- 6; PMID:22720258; http://dx.doi.org/10.4161/onci.1.2.18309
14. Mamessier E, Bertucci F, Sabatier R, Birnbaum D, Olive D. "Stealth" tumors: Breast cancer cells shun NK-cells anti-tumor immunity. Oncoimmunology 2012; 1:366-8; PMID:22737617; http://dx.doi.org/10.4161/onci.18528
15. Pietra G, Vitale M, Moretta L, Mingari MC. How melanoma cells inactivate NK cells. Oncoimmunology 2012; 1:974-5; PMID:23162776; http://dx.doi.org/10.4161/onci.20405
16. Angell H, Galon J. From the immune contexture to the Immunoscore: The role of prognostic and predictive immune markers in cancer. Curr Opin Immunol 2013; 25:261-7; PMID:23579076; http://dx.doi.org/10.1016/j.coi.2013.03.004
17. Pagès F, Kirilovsky A, Mlecnik B, Asslaber M, Tosolini M, Bindea G, Lagorce C, Wind P, Marliot F, Bruneval P, et al. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol 2009; 27:5944- 51; PMID:19858404; http://dx.doi.org/10.1200/JCO.2008.19.6147
18. Virgin HW, Wherry EJ, Ahmed R. Redefining chronic viral infection. Cell 2009; 138:30-50; PMID:19596234; http://dx.doi.org/10.1016/j.cell.2009.06.036
19. Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 2006; 6:715-27; PMID:16977338; http://dx.doi.org/10.1038/nri1936
20. Imai K, Matsuyama S, Miyake S, Suga K, Nakachi K. Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet 2000; 356:1795-9; PMID:11117911; http://dx.doi. org/10.1016/S0140-6736(00)03231-1
21. Romagné F, André P, Spee P, Zahn S, Anfossi N, Gauthier L, Capanni M, Ruggeri L, Benson DM Jr., Blaser BW, et al. Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. Blood 2009; 114:2667-77; PMID:19553639; http://dx.doi.org/10.1182/ blood-2009-02-206532
22. Benson DM Jr., Hofmeister CC, Padmanabhan S, Suvannasankha A, Jagannath S, Abonour R, Bakan C, Andre P, Efebera Y, Tiollier J, et al. A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma. Blood 2012; 120:4324-33; PMID:23033266; http://dx.doi.org/10.1182/blood-2012-06-438028
23. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, Watier H. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002; 99:754-8; PMID:11806974; http://dx.doi.org/10.1182/blood.V99.3.754
24. Cartron G, Trappe RU, Solal-Céligny P, Hallek M. Interindividual variability of response to rituximab: From biological origins to individualized therapies. Clin Cancer Res 2011; 17:19-30; PMID:21208903; http://dx.doi.org/10.1158/1078-0432.CCR-10-1292
25. Galluzzi L, Senovilla L, Zitvogel L, Kroemer G. The secret ally: Immunostimulation by anticancer drugs. Nat Rev Drug Discov 2012; 11:215- 33; PMID:22301798; http://dx.doi.org/10.1038/nrd3626
26. Neudoerfl C, Mueller BJ, Blume C, Daemen K, Stevanovic-Meyer M, Keil J, Lehner F, Haller H, Falk CS. The Peripheral NK Cell Repertoire after Kidney Transplantation is Modulated by Different Immunosuppressive Drugs. Front Immunol 2013; 4:46; PMID:23450662; http://dx.doi.org/10.3389/fimmu.2013.00046
27. Alter G, Malenfant JM, Altfeld M. CD107a as a functional marker for the identification of natural killer cell activity. J Immunol Methods 2004; 294:15-22; PMID:15604012; http://dx.doi.org/10.1016/j.jim.2004.08.008
28. Bryceson YT, Fauriat C, Nunes JM, Wood SM, Björkström NK, Long EO, Ljunggren HG. Functional analysis of human NK cells by flow cytometry. Methods Mol Biol 2010; 612:335-52; PMID:20033652; http://dx.doi.org/10.1007/978-1-60761-362-6_23
29. Claus M Watzl C. Evaluation of human natural killer cell activities in whole blood. Curr. Protoc. Immunol. Ed. John E Coligan Al 2010;Chapter 7:Unit7.39.
30. Eberlein J, Nguyen TT, Victorino F, Golden-Mason L, Rosen HR, Homann D. Comprehensive assessment of chemokine expression profiles by flow cytometry. J Clin Invest 2010; 120:907-23; PMID:20197626; http://dx.doi.org/10.1172/JCI40645
31. Caligiuri MA. Human natural killer cells. Blood 2008; 112:461-9; PMID:18650461; http://dx.doi.org/10.1182/blood-2007-09-077438
32. Béziat V, Dalgard O, Asselah T, Halfon P, Bedossa P, Boudifa A, Hervier B, Theodorou I, Martinot M, Debré P, et al. CMV drives clonal expansion of NKG2C+ NK cells expressing self-specific KIRs in chronic hepatitis patients. Eur J Immunol 2012; 42:447-57; PMID:22105371; http://dx.doi.org/10.1002/eji.201141826
33. Björkström NK, Lindgren T, Stoltz M, Fauriat C, Braun M, Evander M, Michaëlsson J, Malmberg KJ, Klingström J, Ahlm C, et al. Rapid expansion and long-term persistence of elevated NK cell numbers in humans infected with hantavirus. J Exp Med 2011; 208:13-21; PMID:21173105; http://dx.doi. org/10.1084/jem.20100762
34. Sanchez CJ, Le Treut T, Boehrer A, Knoblauch B, Imbert J, Olive D, Costello RT. Natural killer cells and malignant haemopathies: a model for the interaction of cancer with innate immunity. Cancer Immunol Immunother 2011; 60:1-13; PMID:20697893; http://dx.doi.org/10.1007/s00262-010-0898-x
35. Stojanovic A, Correia MP, Cerwenka A. Shaping of NK cell responses by the tumor microenvironment. Cancer Microenviron 2013; 6:135-46; PMID:23242671; http://dx.doi.org/10.1007/s12307-012-0125-8
36. Juelke K, Killig M, Luetke-Eversloh M, Parente E, Gruen J, Morandi B, et al. CD62L expression identifies a unique subset of polyfunctional CD56dim NK cells. Blood 2010; 116: 1299-307; PMID:20651077; http://dx.doi.org/10.1182/blood-2009-11-253286
37. Björkström NK, Riese P, Heuts F, Andersson S, Fauriat C, Ivarsson MA, Björklund AT, Flodström- Tullberg M, Michaëlsson J, Rottenberg ME, et al. Expression patterns of NKG2A, KIR, and CD57 define a process of CD56dim NK-cell differentiation uncoupled from NK-cell education. Blood 2010; 116:3853-64; PMID:20505160; http://dx.doi. org/10.1182/blood-2010-04-281675
38. Björkström NK, Fauriat C, Bryceson YT, Sandberg JK, Ljunggren HG, Malmberg KJ. Analysis of the KIR repertoire in human NK cells by flow cytometry. Methods Mol Biol 2010; 612:353-64; PMID:20033653; http://dx.doi. org/10.1007/978-1-60761-362-6_24
39. Ribeiro-dos-Santos P, Turnbull EL, Monteiro M, Legrand A, Conrod K, Baalwa J, Pellegrino P, Shaw GM, Williams I, Borrow P, et al. Chronic HIV infection affects the expression of the 2 transcription factors required for CD8 T-cell differentiation into cytolytic effectors. Blood 2012; 119:4928-38; PMID:22490682; http://dx.doi.org/10.1182/blood-2011-12-395186
40. Critchley-Thorne RJ, Yan N, Nacu S, Weber J, Holmes SP, Lee PP. Down-regulation of the interferon signaling pathway in T lymphocytes from patients with metastatic melanoma. PLoS Med 2007; 4:e176; PMID:17488182; http://dx.doi.org/10.1371/journal.pmed.0040176
41. Gillard-Bocquet M, Caer C, Cagnard N, Crozet L, Perez M, Fridman WH, Sautès-Fridman C, Cremer I. Lung tumor microenvironment induces specific gene expression signature in intratumoral NK cells. Front Immunol 2013; 4:19; PMID:23382731; http:// dx.doi.org/10.3389/fimmu.2013.00019
42. Rutella S, Locatelli F. Targeting multiple-myelomainduced immune dysfunction to improve immunotherapy outcomes. Clin Dev Immunol 2012; 2012:196063; PMID:22567028; http://dx.doi.org/10.1155/2012/196063
43. Carbone E, Neri P, Mesuraca M, Fulciniti MT, Otsuki T, Pende D, Groh V, Spies T, Pollio G, Cosman D, et al. HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells. Blood 2005; 105:251-8; PMID:15328155; http://dx.doi. org/10.1182/blood-2004-04-1422
44. Famularo G, D'Ambrosio A, Quintieri F, Di Giovanni S, Parzanese I, Pizzuto F, Giacomelli R, Pugliese O, Tonietti G. Natural killer cell frequency and function in patients with monoclonal gammopathies. J Clin Lab Immunol 1992; 37:99-109; PMID:1285130
45. King MA, Radicchi-Mastroianni MA. Natural killer cells and CD56+ T cells in the blood of multiple myeloma patients: analysis by 4-colour flow cytometry. Cytometry 1996 26:121-4; PMID:8817087; http://dx.doi.org/10.1002/SICI)1097-0320(19960615)26:2121: :AIDCYTO4 3.0.CO;2-J
46. Frassanito MA, Silvestris F, Cafforio P, Silvestris N, Dammacco F. IgG M-components in active myeloma patients induce a down-regulation of natural killer cell activity. Int J Clin Lab Res 1997; 27:48-54; PMID:9144027; http://dx.doi.org/10.1007/BF02827242
47. Sawanobori M, Suzuki K, Nakagawa Y, Inoue Y, Utsuyama M, Hirokawa K. Natural killer cell frequency and serum cytokine levels in monoclonal gammopathies: correlation of bone marrow granular lymphocytes to prognosis. Acta Haematol 1997; 98:150-4; PMID:9352746; http://dx.doi. org/10.1159/000203610
48. Fauriat C, Mallet F, Olive D, Costello RT. Impaired activating receptor expression pattern in natural killer cells from patients with multiple myeloma. Leukemia 2006; 20:732-3; PMID:16437151; http://dx.doi. org/10.1038/sj.leu.2404096
49. Jinushi M, Vanneman M, Munshi NC, Tai YT, Prabhala RH, Ritz J, Neuberg D, Anderson KC, Carrasco DR, Dranoff G. MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma. Proc Natl Acad Sci U S A 2008; 105:1285-90; PMID:18202175; http://dx.doi.org/10.1073/pnas.0711293105
50. Jurisic V, Srdic T, Konjevic G, Markovic O, Colovic M. Clinical stage-depending decrease of NK cell activity in multiple myeloma patients. Med Oncol 2007; 24: 312-7; PMID:17873307; http://dx.doi.org/10.1007/s12032-007-0007-y
51. von Lilienfeld-Toal M, Frank S, Leyendecker C, Feyler S, Jarmin S, Morgan R, Glasmacher A, Märten A, Schmidt-Wolf IG, Brossart P, et al. Reduced immune effector cell NKG2D expression and increased levels of soluble NKG2D ligands in multiple myeloma may not be causally linked. Cancer Immunol Immunother 2010; 59:829-39; PMID:20024547; http://dx.doi.org/10.1007/s00262-009-0807-3
52. Pessoa de Magalhães RJ, Vidriales MB, Paiva B, Fernandez-Gimenez C, García-Sanz R, Mateos MV, Gutierrez NC, Lecrevisse Q, Blanco JF, Hernández J, et al.; Spanish Myeloma Group (GEM); Grupo Castellano-Leones de Gammapatias Monoclonales, cooperative study groups. Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry. Haematologica 2013; 98:79-86; PMID:22773604; http://dx.doi.org/10.3324/haematol.2012.067272
53. Benson DM Jr., Bakan CE, Mishra A, Hofmeister CC, Efebera Y, Becknell B, Baiocchi RA, Zhang J, Yu J, Smith MK, et al. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: A therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood 2010; 116:2286-94; PMID:20460501; http://dx.doi.org/10.1182/blood-2010-02-271874
54. Krieg S, Ullrich E. Novel immune modulators used in hematology: Impact on NK cells. Front Immunol 2012; 3:388; PMID:23316191
55. Davies FE, Raje N, Hideshima T, Lentzsch S, Young G, Tai YT, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001; 98: 210-6; PMID:11418482; http://dx.doi.org/10.1182/blood.V98.1.210
56. Hayashi T, Hideshima T, Akiyama M, Podar K, Yasui H, Raje N, Kumar S, Chauhan D, Treon SP, Richardson P, et al. Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br J Haematol 2005; 128:192-203; PMID:15638853; http://dx.doi.org/10.1111/j.1365-2141.2004.05286.x
57. Reddy N, Hernandez-Ilizaliturri FJ, Deeb G, Roth M, Vaughn M, Knight J, Wallace P, Czuczman MS. Immunomodulatory drugs stimulate natural killercell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the antitumour activity of rituximab in vivo. Br J Haematol 2008; 140:36-45; PMID:17995965
58. Zhang L, Qian Z, Cai Z, Sun L, Wang H, Bartlett JB, Yi Q, Wang M. Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo. Am J Hematol 2009 84:553-9; PMID:19565649; http://dx.doi.org/10.1002/ajh.21468
59. Lioznov M, El-Cheikh J, Hoffmann F, Hildebrandt Y, Ayuk F, Wolschke C, et al. Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44(+)) and T (HLA-DR(+)) cells. Bone Marrow Transplant 2010; 45: :349-53; PMID:19584825; http://dx.doi.org/10.1038/bmt.2009.155
60. Wolschke C, Stübig T, Hegenbart U, Schönland S, Heinzelmann M, Hildebrandt Y, Ayuk F, Atanackovic D, Dreger P, Zander A, et al. Postallograft lenalidomide induces strong NK cell-mediated antimyeloma activity and risk for T cell-mediated GvHD: Results from a phase I/II dose-finding study. Exp Hematol 2013; 41:134-42, e3; PMID:23085463; http:// dx.doi.org/10.1016/j.exphem.2012.10.004
61. Gandhi AK, Kang J, Capone L, Parton A, Wu L, Zhang LH, Mendy D, Lopez-Girona A, Tran T, Sapinoso L, et al. Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function. Curr Cancer Drug Targets 2010; 10:155-67; PMID:20088798; http://dx.doi.org/10.2174/156800910791054239
62. Hsu AK, Quach H, Tai T, Prince HM, Harrison SJ, Trapani JA, Smyth MJ, Neeson P, Ritchie DS. The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy. Blood 2011; 117:1605-13; PMID:20978269; http://dx.doi.org/10.1182/ blood-2010-04-278432